Taiga Biotechnologies, Inc.

University of Colorado

National Jewish Health

Htyr Acquisition LLC

Htyr Acquistion LLC

Yosef Refaeli

Brian Curtis Turner

Gregory Alan Bird

John C Cambier

Xiao-Jing Wang

Qinghong Zhang

Sara Ann Johnson

Thomas R Payne

METHODS FOR REDUCING ANERGY IN LYMPHOCYTES USING MODULATORS OF MYC

Provided herein are compositions and methods for treating T cell exhaustion in a subject, by administering a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) or immune cells treated with a PTD-MYC fusion protein. Kits for use in practicing the methods are also provided herein.

Compositions and methods for treating T cell exhaustion

This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.

Nanoparticle formulations

Provided herein are compositions and methods for the cryopreservation of immune cells, such as peripheral blood mononuclear cells (PBMCs) by pre-treating the cells with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) prior to freezing. Kits for practicing the methods are also provided herein.

Compositions and methods for the cryopreservation of immune cells

Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.

Antibodies and processes for preparing the same

Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.

Compositions and methods for modulating immune cells

The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.

Enhanced reconstitution and autoreconstitution of the hematopoietic compartment

Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).

Methods and compositions for the treatment of melanoma

The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.

Production and use of red blood cells

Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.

Conditionally immortalized long-term stem cells and methods of making and using such cells

Compositions and methods for modulating an immune response

The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Growing community of inventors

Denver, CO, United States of America

Yosef Refaeli